EGFR and cancer: Additionally, while the concomitant pharmacological blockade upstream and downstream of the mutated KRAS emerged as a potential strategy to achieve a complete EGFR axis inhibition, the identification of tumor‐derived mutated DNA in the bloodstream of patients allowed to monitor for the first time the genetic evolution of cancer [9, 10].